No problem, C. I truly like the Algovita system, and I rank it #2 behind Boston Scientific; across the entire marketplace. THAT is the reason to invest in NVTR, instead of Boston Sci. Reasoning- for being "#2" in terms of quality, their market cap is currently ranking them in LAST PLACE. I still honestly believe in an eventual 1-2 billion valuation, OR a buyout in range of 500 million- 1.5 billion---based on tech and IP alone. Just not certain how long that will take.